Exagen Inc. XGN Weighted Average Exercise Price of Exercisable Options
Weighted Average Exercise Price of Exercisable Options at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice.
The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exagen Inc.'s weighted average exercise price of exercisable options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exagen Inc.'s weighted average exercise price of exercisable options?
- Exagen Inc. (XGN) reported weighted average exercise price of exercisable options of $7.68 in Q1 2026.
- How has Exagen Inc.'s weighted average exercise price of exercisable options changed year-over-year?
- Exagen Inc.'s weighted average exercise price of exercisable options decreased by 10.7% year-over-year, from $8.60 to $7.68.
- What is the long-term trend for Exagen Inc.'s weighted average exercise price of exercisable options?
- Over 5 years (2020 to 2025), Exagen Inc.'s weighted average exercise price of exercisable options has grown at a 3.6% compound annual growth rate (CAGR), from $6.75 to $8.07.
- What does weighted average exercise price of exercisable options mean?
- The average exercise price for all share-based options that are currently eligible for immediate conversion into common stock. This metric indicates the price threshold at which current option holders may choose to exercise their rights. It is useful for modeling potential near-term dilution and cash inflows from option exercises.